CR3022 |
C-Terminal RBD, 318-510 amino acid residue, Showed cross
reactivity with SARS-CoV-2 |
48 |
F26G18 |
C-Terminal of RBD, 460-476 amino acid residues |
52 |
4D4 |
N-Terminal of RBD, 12-261 amino acid residues, inhibiting the
post-interaction in the viral penetration in vitro |
53 |
CR3014 |
C-terminal of RBD, 318-510 amino acid residues and 565 amino
acid residue (high affinity) but do not showed cross reactive to
SARS-CoV-2 |
48,50 |
68 |
130-150 of the amino acid residues |
54 |
80R |
C-Terminal of RBD, 426-492 amino acid residues, blocking the
interaction of S1 subunit protein with cellular receptor ACE2 using 6
complementary determining region (CDR) in vitro and in vivo (Mouse |
55 |
F26G19 |
C-Terminal of RBD, 359-362, 391-392, 424-427, and 486-492 amino
acid residues |
52 |
201 |
C-Terminal of RBD, 490-510 amino acid residues, |
56 |
1A9 |
Binding to the Heptad repeat (HR) loops including heptad repeat 1
(HR1) and heptad repeat 1 (HR2) domain on S2 fragment, 1111-1130 amino
acid residues |
57,58 |
S230 |
Binding to epitopes partially overlapping with receptor binding
motifs on B domain of SARS-CoV-1, Blocking the interaction of S1 subunit
protein with cellular receptor ACE2 in vitro |
59 |
m396 |
C-Terminal, 482-491 amino acid residues |
51,52 |